International Clinical Trial: A Phase 1, 3-Part, Adaptive Design, Drug-Drug Interaction Study to Assess the Effect of Acid Reducing Agents and CYP1A2 Inhibition on the Pharmacokinetics of ATH434 in Healthy Subjects

Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ACTRN12626001265369) titled 'A Phase 1, 3-Part, Adaptive Design, Drug-Drug Interaction Study to Assess the Effect of Acid Reducing Agents and CYP1A2 Inhibition on the Pharmacokinetics of ATH434 in Healthy Subjects' on Oct. 21.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Non-randomised trial Masking: Open (masking not used) Assignment: Crossover

Primary Sponsor: Alterity Therapeutics Limited

Condition: Multiple System Atrophy (MSA) Multiple System Atrophy (MSA) Neurological - Neurodegenerative diseases

Intervention: Period 1 (Day 1): Participants will receive a single oral dose of 50mg ATH434 tablet. Inter...